Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.
Cancellation of kids’ asthma medication continues to cause turmoil for Mass. families
Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...
Sell Rating for GlaxoSmithKline Amidst Competitive Pressures from Gilead in HIV Market
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
pharmaphorum2d
FDA clears GSK's Priorix, first new MMR vaccine in 50 years
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
WJET Erie on MSN2mon
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
BBC2y
Marmite-owner Unilever makes three bids for GSK consumer goods arm
GlaxoSmithKline has rejected three Unilever offers to buy its consumer goods division, including one worth £50bn. GSK said the proposals "fundamentally failed" to reflect the value of the division.
Nature3y
How GlaxoSmithKline is advancing efficient drug development in haematologic malignancies
At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...